CRISPR Therapeutics(CRSP) - 2023 Q1 - Quarterly Report

Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the transition period from to . (State or other jurisdiction of incorporation or organization) Baarerstrasse 14 6300 Zug, Switzerland Not Applicable (Address of principal executive offices) (Zip Code) Switzerland Not Applicable (I.R.S. Employer Identification No.) +41 (0)41 561 32 77 (R ...